sponsored by National Natural Science Foundation of China(Grant Numbers 81972280,81972290);Natural Science Foundation of Shanghai(Grant Number 23ZR1452300);Research Grant for Health Science and Technology of Pudong Health Bureau of Shanghai(Grant Number PW2022E-02);Academic Leaders Training Program of Pudong Health Bureau of Shanghai(Grant Number PWRd2022-02);Foundation of Beijing CSCO Clinical Oncology Research(Grant Number Y-HR2019-0384).
Objectives:Human epidermal growth factor receptor 2(HER2)-targeted therapies have demonstrated potential benefits for metastatic colorectal cancer(mCRC)patients with HER2 amplification,but are not satisfactory in case...
Human epidermal growth factor receptor 2 (HER2) is a major drug target and clinical biomarker in breast cancertreatment. Targeting HER2 gene amplification is one of the greatest successes in oncology, resulting in the...